Treatment
Ustekinumab
4
Conditions
304
Trials
40K
Participants
58%
Average Safety
Condition Evidence
Crohn's Disease
78 trials · 8,000 participants
72% effectiveness · 50% safety
Inflammatory bowel disease
100 trials · 10K participants
77% effectiveness · 60% safety
Psoriasis
94 trials · 20K participants
80% effectiveness · 57% safety
Ulcerative Colitis
32 trials · 2,000 participants
75% effectiveness · 65% safety